EXAS vs PRTA · rev $2.76B vs rev $1.0M
EXACT Sciences Corporation (EXAS) versus Prothena Corporation plc (PRTA) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Prothena Corporation plc (PRTA) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported PRTA revenue for 2026-06-30 was $1.0M. Net income was -$18.6M. Revenue was down 98.0% from 2026-03-31 to 2026-06-30. PRTA currently screens at market cap $460.2M.
EXAS currently screens at market cap $20.03B. PRTA currently screens at market cap $460.2M.
Not investment advice. Open the EXAS and PRTA stock pages for the full models.
Not investment advice.